A trusted leader advancing the industry through science
Emerald Health Sciences has launched or acquired companies worldwide that are leading the way in developing innovative pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system. Each company within our portfolio leverages the scientific rigor and life-science expertise of our leadership.
Our portfolio spans continents and sectors
As a part of our commitment, we work in partnership with each of our companies to provide knowledge, skill and resources to ensure their success and growth as pioneers in their respective cannabis industry sectors – cultivation, consumer products, research and development, pharmaceuticals and analytical testing. Together we are the Emerald Group of Companies, and through our combined success our aim is to enhance the health of others through innovation in cannabis science.
November 4, 2018
Future of Legal Marijuana: Canadian Greenhouses Could Mean Cheaper, Safer Pot
The red-leafed blueberry bushes and greenhouses filled with tomatoes tell you that this small town south of Vancouver is a great place to grow things. [read more]
November 14, 2018
Cannabis Vaping Laws Frustrate B.C. Entrepreneurs
Canada’s rules around cannabis vaping are frustrating entrepreneurs and putting consumers’ health at risk, according to those in the industry. [read more]
October 8, 2018
Developing Cannabinoid Derivative EHP-101 for Multiple Sclerosis
With a phase I trial of the therapy underway, EHP-101 is one step closer to potentially showing an effect on the pathology of multiple sclerosis. [read more]
Sign up today and receive all of Emerald’s latest news and events directly to your inbox.